Recordati confirms acceptance period ended with shareholding at 74.58%
Respighi BidCo reached the 66.67% threshold alongside CVC and GBL. The company announces terms reopening for further actions.
See the latest news and media coverage for Recordati. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company developing and commercialising medicines
recordati.comLast updated
In short: Recordati's CVC/GBL takeover bid via Respighi BidCo reached 74.58% shareholding, clearing the path toward delisting.
Respighi BidCo reached the 66.67% threshold alongside CVC and GBL. The company announces terms reopening for further actions.
Respighi BidCo S.p.A signed a sale and purchase agreement for approximately 0.66% of Recordati SPA share capital on October 16, 2026.
Net sales rose 18.9% to €254 million and net income increased 18.3%. Pharmaceutical sales surged 25.3%, driven by lercanidipine success and new product launches across international markets.
Net sales rose 36.4% to 413.7 billion lire while EBITDA increased 68.2%, driven by international pharmaceutical expansion.
The delisting merger discussed today in Sole24Ore would require the opinion of independent parties. The offer at €53 compares with our target price of...
Respighi reaches 74.58% of Recordati. Opa at 53 euros reopened from November 3 to 9, debt of 6.05 billion and possible merger.
For analysts, the price offered by Cvc and Gbl remains inadequate, but pressure is mounting to deliver the shares...
The offer gives control of the extraordinary shareholders' meeting and allows for the company's delisting through an inverse merger. Now the reopening of the Opa...
Track Recordati and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Recordati and other trending companies.